<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article302</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/IALT" style="display:block; margin-bottom:10px;">IALT Original</a></li>
<h2><strong>IALT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer".The New England Journal of Medicine. 2004. 350:351-360.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcome<br/>
8.2Secondary Outcomes<br/>
9Criticisms<br/>
10Funding<br/>
11Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does cisplatin-based adjuvant chemotherapy improve survival among patients with completely resected non-small-cell lung cancer?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Cisplatin-based adjuvant chemotherapy provides a slight improvement in survival for patients with completely resected non-small-cell lung cancer.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff date for this summary, guidelines regarding the use of adjuvant chemotherapy in non-small-cell lung cancer should be consulted for the most up-to-date recommendations.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, open-label, controlled trial<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
A total of 1867 patients with completely resected non-small-cell lung cancer.<br/>
<br/>
Inclusion Criteria<br/>
- Pathologically documented non-small-cell lung cancer of stage I, II, or III<br/>
- Complete surgical resection<br/>
- Age between 18 and 75 years<br/>
- No previous chemotherapy or radiotherapy<br/>
- No other previous cancers except nonmelanoma skin cancer or carcinoma in situ of the cervix<br/>
<br/>
Exclusion Criteria<br/>
- Contraindications to chemotherapy<br/>
- Ineligibility as determined by other clinical factors<br/>
<br/>
Baseline Characteristics<br/>
- The study population had stages I, II, or III non-small-cell lung cancer<br/>
- The median duration of follow-up was 56 months<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Randomly assigned to:<br/>
- Cisplatin-based chemotherapy (n=932) — three or four cycles<br/>
- Observation (n=935)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Overall five-year survival rates: 44.5% in the chemotherapy group vs. 40.4% in the observation group (P&lt;0.03)<br/>
<br/>
Secondary Outcomes<br/>
- Disease-free survival rates at five years: 39.4% in the chemotherapy group vs. 34.3% in the observation group (P&lt;0.003)<br/>
- No significant interactions with prespecified factors<br/>
- Chemotherapy-induced deaths: 0.8%<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Open-label design<br/>
- Selection of adjuvant therapy and radiotherapy was not uniform across centers<br/>
- Potential for confounding by differences in radiotherapy administration<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by unrestricted grants from various cancer research associations and institutions.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
